CrossLend Structures an Investment Grade Rated ESG Note for Bikeleasing and MEAG as a Digital Asset
12.10.2021 12:24:00 EEST | Business Wire | Press release
Berlin-based FinTech CrossLend has issued a note to facilitate an investment into lease contracts for bicycles. The transaction is the result of a collaboration between Bikeleasing - the fastest growing e-bike leasing provider, MEAG as asset manager, ERGO as investor, and CrossLend as the structurer and operator of the digital register. Scope rated the note as investment grade and confirmed the ecological impact of the issued note is in accordance with the ICMA Green Bond Principles as part of a second party opinion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211012005499/en/
Marco Hinz (Chief Operating Officer) and Oliver Schimek (Chief Executive Officer & Founder), CrossLend GmbH (Photo: Business Wire)
The transaction reflects several market trends. The goals of a climate-neutral society require substantial investments to replace goods such as cars or heating devices which, in their normal lifespan, would still have years of operation ahead of them. At the same time, cost-intensive innovative products are being offered as part of convenient pay-as-you-go models which contain a lending product and require refinancing. As a result, highly innovative originators such as Bikeleasing are entering into an origination model in competition with banks, or even closing gaps where traditional banking products are not covering the needs of customers. The kinetics in terms of origination frequency, and the level of fragmentation seen in the single tickets of such originations, require a digital and data-driven transactional link to traditional capital market investors. Accordingly, CrossLend structured and issued a note on its digital asset register which complied with the ICMA Green Bond Principles.
"The transformation of the economy and society towards climate-friendly technologies requires unparalleled investments in a relatively short period of time. The reality is that non-digital investment banking cannot keep up with the kinetics of innovative product providers such as Bikeleasing. We are extremely proud that our digital asset technology closes a gap between agile, transformative products and the capital markets, enabling established institutions like MEAG and ERGO to conveniently invest to support ecological change," says Oliver Schimek, Chief Executive Officer of CrossLend GmbH.
According to Thomas Bayerl, Head of Illiquid Assets Debt at MEAG: "As an asset manager, we work in an environment where digital transformation and sustainability criteria play an increasing role in the development of investable assets. CrossLend's digital asset platform and register were instrumental in making this asset accessible for our client ERGO today. This transaction can serve as a successful example for further implementation possibilities in a variety of industries."
Paul Sinizin, co-founder and CEO of Bikeleasing comments: "Bikeleasing has been growing extremely fast and we still see a large untapped market opportunity ahead. For our growth we require a flexible and scalable funding source. Working with a technology platform like CrossLend allows us to minimise our operational efforts on the capital markets activity through automation and industrialisation."
About CrossLend
CrossLend is a FinTech company that provides full spectrum technology for loan asset transactions. Its mission is to make the world's lending and investment ecosystem more efficient, transparent, and profitable. Supervised by BaFIN and CSSF, CrossLend is backed by an array of prestigious equity investors from Europe and the US, including Mouro Capital (formerly Santander InnoVentures), Lakestar, CME Ventures, Earlybird, ABN AMRO's Digital Impact Fund, and the Luxembourg Future Fund (EIF and SNCI).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005499/en/
Contact information
Media officer
Agnieszka Szczesna
Tel: +49 30 208 488 133
media@crosslend.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
